Psilacetin - Psilera
Latest Information Update: 19 Sep 2022
At a glance
- Originator Psilera
- Class Behavioural disorder therapies; Drug withdrawal therapies; Indole alkaloids; Mood stabilisers; Small molecules; Tryptamines
- Mechanism of Action 5-HT1 serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Substance-related disorders
Most Recent Events
- 14 Sep 2022 Psilera receives patent allowance for DMT and psilacetin transdermal patch formulations in USA
- 15 Mar 2022 Psilera has patents pending for psilacetin prior to March 2022 (Psilera pipeline, March 2022)
- 15 Mar 2022 Preclinical trials in Substance-related disorders in USA (Transdermal) prior to March 2022 (Psilera pipeline, March 2022)